Heart Failure
RSSArticles
-
Avoid Trouble: Choose Reteplase Candidates with Care
-
Reteplase is an early prognostic indicator
-
Clot-busters nearly equal, GUSTO report shows
-
Reteplase achieves patency, reduces mortality
-
Profiling moves from defense to offense
-
Clopidogrel pricey, but may edge aspirin
-
At a cost of only $400, new EBCT scan challenges the angiogram
-
EBCT costs one-fifth of an angiogram
-
Middletown team refines its system
-
EBCT reimbursement is, at best, dicey